PT - JOURNAL ARTICLE AU - Katia Gagnon AU - Andrée-Ann Baril AU - Jacques Montplaisir AU - Julie Carrier AU - Sirin Chami AU - Serge Gauthier AU - Chantal Lafond AU - Jean-François Gagnon AU - Nadia Gosselin TI - Detection of mild cognitive impairment in middle-aged and older adults with obstructive sleep apnea AID - 10.1183/13993003.01137-2018 DP - 2018 Jan 01 TA - European Respiratory Journal PG - 1801137 4099 - http://erj.ersjournals.com/content/early/2018/08/23/13993003.01137-2018.short 4100 - http://erj.ersjournals.com/content/early/2018/08/23/13993003.01137-2018.full AB - Obstructive sleep apnea increases the risk for mild cognitive impairment and dementia. The present study aimed at characterising the ability of two cognitive screening tests, the Mini-Mental State Examination and Montreal Cognitive Assessment, to detect mild cognitive impairment in adults aged 55 to 85 years with versus without obstructive sleep apnea.We included 42 subjects with mild and 67 subjects with moderate to severe obstructive sleep apnea. We compared them to 22 control subjects. Mild cognitive impairment was diagnosed with a comprehensive neuropsychological assessment. We used receiver operating characteristic curves to assess screening test abilities to detect mild cognitive impairment.Both screening tests showed similar discriminating abilities in controls. However, among the mild and the moderate to severe obstructive sleep apnea groups, the Mini-Mental State Examination was not able to correctly identify subjects with mild cognitive impairment. The Montreal Cognitive Assessment's discriminant ability was acceptable in both sleep apnea groups and was comparable to what was observed in controls.The Mini-Mental State Examination should not be used to screen for cognitive impairment in patients with obstructive sleep apnea. The Montreal Cognitive Assessment could be used in clinical settings. However, clinicians should refer to neuropsychology when neurodegenerative processes are suspected.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Baril reports personal fees from Canadian Institutes of Health Research, personal fees from Fonds de la Recherche en Santé du Québec, during the conduct of the study.Conflict of interest: Dr. Carrier reports other from RANA, other from Respironics, other from Merck, outside the submitted work.Conflict of interest: Dr. Chami has nothing to disclose.Conflict of interest: Dr. Gagnon reports grants from W. Garfield Weston Foundation, grants from Canadian Institutes of Health Research, grants from Canada Research Chair, grants from Fonds de Recherche du Québec - Santé, during the conduct of the study.Conflict of interest: Dr. Gagnon has nothing to disclose.Conflict of interest: Dr. Serge reports grants from Canadian Institutes of Health Research, during the conduct of the study; grants from CQDM network and research grant, grants from Pfizer-Fond de Recherche Santé -Québec, grants from Canadian Institutes of Health Research, personal fees from Lilly, personal fees from Roche, personal fees from TauRx, personal fees from Lundbeck, personal fees from AbbVie, personal fees from ADvantage, personal fees from Alzheon, personal fees from Axovant, personal fees from Boehringer-Ingelheim, personal fees from Firalis, personal fees from Heptares, personal fees from IntelGen, personal fees from Klagene, personal fees from Novartis, personal fees from Otsuka, personal fees from Servier, personal fees from Sanofi, personal fees from Schwabe, personal fees from Takeda, non-financial support from Alzheimer's Disease Cooperative Study, non-financial support from Alzheimer'S Disease Therapeutic Research Institute, outside the submitted work.Conflict of interest: Dr. Gosselin reports grants from Canadian Institutes of Health Research, grants from Fonds de Recherche en Santé du Québec, during the conduct of the study.Conflict of interest: Dr. Lafond has nothing to disclose.Conflict of interest: Dr. MONTPLAISIR reports personal fees from Novartis, personal fees from Merck Pharmaceutical, personal fees from Otsuka Pharmaceutical, outside the submitted work.